Bayer gets first-line approval for Sevabertinib in China for HER2-mutated NSCLC

China's National Medical Products Administration granted approval for Bayer's Sevabertinib as a first-line treatment for patients with advanced HER2-mutated non-small cell lung cancer. Bayer's head of pharmaceutical research, Christian Rommel, said the approval is a significant advancement for patients in China with this subtype, which frequently affects non-smokers.

Detected & updated continuously · Source: Nebula